

GLAXOSMITHKLINE PLC  
Form 6-K  
January 05, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending January 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 31 December 2009, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depository Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2009:

GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award - Annual Dividend Reinvestment

| Non-Executive Director | No. of Ordinary Shares | Average Price (£) | No. of ADSs | Average Price (\$) |
|------------------------|------------------------|-------------------|-------------|--------------------|
| Sir Christopher Gent   | 1,822.44               | 13.25             |             |                    |
| Prof Sir Roy Anderson  | 151.12                 | 13.25             |             |                    |
| Dr Stephanie Burns     |                        |                   | 158.38      | 42.40              |
| Mr Lawrence Culp       |                        |                   | 717.14      | 42.40              |
| Sir Crispin Davis      | 1,501.48               | 13.25             |             |                    |
| Sir Deryck Maughan     |                        |                   | 628.85      | 42.40              |
| Mr James Murdoch       | 2.13                   | 13.25             |             |                    |
| Dr Daniel Podolsky     |                        |                   | 263.63      | 42.40              |
| Mr Tom de Swaan        | 277.24                 | 13.25             |             |                    |
| Sir Robert Wilson      | 424.27                 | 13.25             |             |                    |

The Company and the Non-Executive Directors were informed of these allocations on 4 January 2010.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell

Company Secretary

5 January 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: January 05, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc